KR102608839B1 - Composition for prevention and treatment of atopic dermatitis of companion dog - Google Patents

Abstract

The purpose of the present invention is to provide a composition for alleviating and treating atopic dermatitis in dogs. In the composition for alleviating and treating atopic dermatitis in dogs, a composition containing honeysuckle, eucalyptus, gardenia, and lilac is provided, and administering the composition to a dog is effective in treating atopic dermatitis in dogs.

Description

Composition for relieving and treating atopic dermatitis in dogs {COMPOSITION FOR PREVENTION AND TREATMENT OF ATOPIC DERMATITIS OF COMPANION DOG}

The present invention relates to a composition for alleviating and treating atopic dermatitis in dogs.

As dogs' outdoor activities increase and they are exposed to external fine dust, pollen, and harmful substances, their skin diseases are also increasing and their health is threatened. Among them, atopic dermatitis is the most common allergic skin disease suffered by dogs. Allergy symptoms manifest as eczematous skin, and canines such as dogs with atopic dermatitis often suffer from pruritus, severe itching, hair loss, peeling of the skin, frequent licking, and excessive tear production. Secondary skin problems also occur, including skin infections and excessive sebum secretion.

Due to these problems, research is being conducted on compositions for alleviating and treating atopic dermatitis in dogs, and prior literature (Publication No. '10-2019-0003948', Publication No. '10-2021-0050574', etc.) Although this is disclosed, the more diverse active ingredients are added, the more diverse reactions may occur when a dog ingests the composition. Therefore, there is a need for a composition that can effectively treat atopic dermatitis.

The purpose of the present invention is to provide a composition for alleviating and treating atopic dermatitis in dogs.

The present invention can provide a composition for alleviating and treating atopic dermatitis in dogs, including honeysuckle, honeysuckle, gardenia, and white chrysanthemum.

The present invention can also provide a composition for alleviating and treating atopic dermatitis in dogs, including honeysuckle, honeysuckle, gardenia, and baekchulman.

Preferably, based on 100 parts by weight of the gold and silver coins, it may include 37 to 120 parts by weight of mold opening, 37 to 120 parts by weight of gardenia, and 47 to 120 parts by weight of Baekchul.

Preferably, the composition may be any one formulation selected from the group consisting of powder, decoction, liquid, tablet, nutritional supplement, and jerky.

Preferably, 0.9 to 1.1 g of the composition is administered to a dog weighing 0 to 3 kg, and if the dog weighs more than 3 kg, 0.3 g of the composition is added for each 1 kg increase in weight. It can be administered.

The present invention can alleviate and treat atopic dermatitis in dogs by providing a composition containing honeysuckle, honeysuckle, gardenia, and white twig.

Figure 1 is a graph comparing the area of atopic dermatitis in dogs before and after ingestion of the liquid formulation prepared according to Example 2.
Figure 2 is a graph comparing atopic dermatitis symptom scores in dogs before and after ingestion of the liquid formulation prepared according to Example 2.

Hereinafter, embodiments of the present invention will be described in detail. However, this is presented as an example, and the present invention is not limited thereby, and the present invention is only defined by the scope of the claims to be described later.

The composition according to one embodiment of the present invention is a composition for alleviating and treating atopic dermatitis in dogs, including honeysuckle, honeysuckle, gardenia, and white chrysanthemum.

In the present invention, the subjects ingesting the composition are animals with skin diseases, and dogs with atopic dermatitis disease are particularly preferable.

In the present invention, honeysuckle is a flower bud or flower that has just begun to bloom of honeysuckle and is widely used in oriental medicine for its various pharmacological effects. It has the effect of reducing fever, so it is effective in the necrosis of skin tissue caused by heat poisoning, and is effective in wind-and-wet arthritis, etc.

In the present invention, Hyeonggae is a plant of the Lamiaceae family that is spicy and bitter in taste and warm in nature. It has been reported to have antipyretic, sweat secretion, blood circulation, antispasmodic, digestive, and antibacterial effects.

In the present invention, gardenia is the dried ripe fruit of gardenia, a plant of the madder family, and has a bitter taste and cold nature. It has effects such as reducing fever, relieving chest tightness, stopping bleeding, and reducing swelling.

In the present invention, Baekchul refers to a medicinal material that has been dried by removing the rhizome or pericarp of the Asteraceae or Baekchul. Baekchul has a unique odor, tastes slightly bitter and sweet, becomes viscous when chewed, and is warm in nature. As for its efficacy, it has been reported to promote cellular immune function, suppress the intestinal tract, regulate excitability, protect anti-ulcer and liver function, enhance immune function, and have anti-cancer activity.

In the present invention, the composition for alleviating and treating atopic dermatitis in dogs includes 57 to 77 parts by weight of Hyeonggae, 57 to 77 parts by weight of Gardenia, and 90 to 110 parts by weight of Baekchul, based on 100 parts by weight of honeysuckle.

Hereinafter, the present invention will be described in detail through examples. The examples are shown to aid understanding of the present invention, and the present invention should not be construed as limited by the examples.

Example 1: Preparation of a composition in powder form

In order to prepare a powder formulation composition, 90 g of honeysuckle, 60 g of mold seeds, 60 g of gardenia, and 90 g of baekchul were each ground, placed in a powder mixer, and mixed to prepare a powder formulation composition.

Example 2: Preparation of liquid formulation

To prepare a total of 20 pieces of composition based on 50 ml of water, 30g of honeysuckle, 20g of mold, 20g of gardenia, and 30g of baekchul were added to 1 L of water, and boiled at 105°C for 150 minutes to form a liquid formulation. was prepared (total 50 packs, 20 ml/pack).

Example 3: Preparation of tablet formulation

In order to prepare a tablet formulation composition, a tablet formulation was prepared from the powder formulation composition prepared in Example 1.

The powder-type composition of Example 1 can be added to various formulations, such as nutritional supplements for dogs or jerky.

Preparation of Examples 4 to 12 and Comparative Examples 1 to 7

Examples 4 to 12 and Comparative Examples 1 to 7 were performed in the same manner as Example 1, but were prepared at the weight ratio shown in Table 1 below, based on the weight of 100 g of gold and silver coins.

Experimental Example 1. NO production inhibition effect

In order to determine the anti-inflammatory effect of the compositions of Examples 1, 4 to 12 and Comparative Examples 1 to 7, the NO production inhibition effect was confirmed. RAW 264.7 cells, which are mouse macrophages, were distributed on 100 mm plates and cultured. Anti-inflammatory activity was evaluated using the NO assay using griess A and B reagent, using a mixture of 1% sulfanilamide and 0.1% N-(1-naphtyl)ethylenediamine dihydrochloride reagent in a 1:1 ratio. After processing Examples 1, 4 to 12 and Comparative Examples 1 to 7 in a 96 well plate, the supernatant of the medium cultured for 24 hours at 37°C and 5% CO ₂ was griess (A+B) 50㎕ of each was mixed with the reagent in a 1:1 ratio and stored at room temperature for 10 minutes, and then the ability to inhibit NO production was measured through ELISA measurement at 540nm. The results are shown in [Table 2] below. The NO production inhibition rate (%) refers to the NO production rate (%) subtracted from 100% based on the control group (100%).

As shown in [Table 2], the compositions of Examples 1 and 4 to 12 showed significantly improved NO production inhibition rates compared to the compositions of Comparative Examples 1 to 4. In particular, it was confirmed that the compositions of Examples 1, 4, 5, and 7 had similar or better NO production inhibition rates than the compositions of Comparative Examples 5 to 7 containing angelica root or dermis.

Experimental Example 2. Comparison of area of atopic dermatitis in dogs

Figure 1 is a graph comparing the area of atopic dermatitis in dogs before and after ingestion of the liquid formulation prepared according to Example 2.

To compare the area of atopic dermatitis in dogs before and after ingestion of the liquid formulation, 28 dogs were targeted and classified according to breed and age. Afterwards, the atopic dermatitis area was calculated in each dog before and after intake, and at the end of 3 months, the atopic dermatitis area was significantly reduced in all dogs.

Experimental Example 3. Comparison of dog atopic dermatitis symptom scores

Figure 2 shows atopic dermatitis in dogs before and after ingestion of the liquid formulation prepared according to Example 2, Apoquel (manufacturer: JSK) and Cytopoint (manufacturer: zoetis), which are existing compositions for the treatment of atopic dermatitis in dogs. This is a graph comparing symptom scores. In Experimental Example 2, the area of atopic dermatitis in dogs was compared and at the same time, atopic dermatitis symptoms were quantified and expressed as scores. Atopic dermatitis symptoms were scored in each dog before and after intake, and it was confirmed that the atopic dermatitis symptom scores were significantly lowered in all dogs after 3 months.

[Table 3] below shows the atopic dermatitis area and symptom score of 28 dogs classified according to breed and age, before and after ingestion of the liquid formulation of Example 2, Apoquel and Cytopoint.

As seen in Experimental Example 3, it was confirmed that the composition of the present invention has a similar effect to Apoquel and Cytopoint, which are existing compositions for the treatment of atopic dermatitis in dogs.

As mentioned above, as specific parts of the present specification have been described in detail, it is clear to those skilled in the art that these specific techniques are merely preferred embodiments and do not limit the scope of the present specification thereby. will be. Accordingly, the actual scope of the present specification will be defined by the appended claims and their equivalents.

Claims (5)

Includes honeysuckle, honeysuckle, gardenia, and white chrysanthemum,
A composition for alleviating and treating atopic dermatitis in dogs, comprising 37 to 120 parts by weight of Hyeonggae, 37 to 120 parts by weight of Gardenia, and 47 to 120 parts by weight of Baekchul, based on 100 parts by weight of honeysuckle. According to paragraph 1,
Contains only honeysuckle, honeysuckle, gardenia, and white chrysanthemum;
A composition for alleviating and treating atopic dermatitis in dogs, comprising 37 to 120 parts by weight of Hyeonggae, 37 to 120 parts by weight of Gardenia, and 47 to 120 parts by weight of Baekchul, based on 100 parts by weight of honeysuckle. delete According to claim 1 or 2,
A composition for alleviating and treating atopic dermatitis in dogs, characterized in that the composition is any one formulation selected from the group consisting of powder, decoction, liquid, tablet, nutritional supplement, and jerky. 0.9 to 1.1 g of the composition of claim 1 or 2 is administered to a dog weighing 0 to 3 kg, and when the dog weighs more than 3 kg, 0.3 g of the composition is administered for each 1 kg increase in weight. A method of alleviating atopic dermatitis in dogs, characterized by administration by adding more.